MAT-CHDSP, a novel medication assessment tool for evaluation of secondary prevention of coronary heart disease

Pharmacoepidemiology and Drug Safety

Volumn 20, Issue 3, 2011, Pages 249-257

  Garcia, Beate Hennie ^a,b   Utnes, June ^b   Naalsund, Liv Unni ^b   Giverhaug, Trude ^c  

^a Hospital Pharmacy of North Norway Trust   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

^c UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

Author keywords

Assessment tool; Coronary heart disease; Guideline; Medication; Pharmaceutical care; Pharmacist; Quality of prescribing; Recommendations; Secondary prevention

Indexed keywords

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL ASSESSMENT TOOL; CONTENT VALIDITY; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICATION ASSESSMENT TOOL CORONARY HEART DISEASE SP; PATIENT COMPLIANCE; PILOT STUDY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RELIABILITY; SECONDARY PREVENTION;

AGED; CORONARY DISEASE; DRUG PRESCRIPTIONS; FEMALE; GUIDELINE ADHERENCE; HUMANS; MALE; NORWAY; PHYSICIAN'S PRACTICE PATTERNS; PILOT PROJECTS; PRACTICE GUIDELINES AS TOPIC; QUALITY ASSURANCE, HEALTH CARE; SECONDARY PREVENTION;

EID: 79951987306     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.2054     Document Type: Article

References (29)

1. Paulino EI, Bouvy ML, Gastelurrutia MA, Guerreiro M, Buurma H. Drug related problems identified by European community pharmacists in patients discharged from hospital. Pharm World Sci 2004; 26(6): 353-360.
2. Hammerlein A, Griese N, Schulz M. Survey of drug-related problems identified by community pharmacies. Ann Pharmacother 2007; 41(11): 1825-1832.
3. Viktil KK, Blix HS, Moger TA, Reikvam A. Interview of patients by pharmacists contributes significantly to the identification of drug-related problems (DRPs). Pharmacoepidemiol Drug Saf 2006; 15(9): 667-674.
4. Hanlon JT, Weinberger M, Samsa GP, et al. A randomized, controlled trial of a clinical pharmacist intervention to improve inappropriate prescribing in elderly outpatients with polypharmacy. Am J Med 1996; 100(4): 428-437.
5. Till LT, Voris JC, Horst JB. Assessment of clinical pharmacist management of lipid-lowering therapy in a primary care setting. J Manag Care Pharm 2003; 9(3): 269-273.
6. Bailey TC, Noirot LA, Blickensderfer A, et al. An intervention to improve secondary prevention of coronary heart disease. Arch Intern Med 2007; 167(6): 586-590.
7. Axtell SS, Ludwig E, Lope-Candales P. Intervention to improve adherence to ACC/AHA recommended adjunctive medications for the management of patients with an acute myocardial infarction. Clin Cardiol 2001; 24(2): 114-118.
8. Chapman NR, Fotis MA, Yarnold PR, Gheorghiade M. Pharmacist interventions to improve the management of coronary artery disease. Am J Health Syst Pharm 2004; 61(24): 2672-2678.
9. Horning KK, Hoehns JD, Doucette WR. Adherence to clinical practice guidelines for 7 chronic conditions in long-term-care patients who received pharmacist disease management services versus traditional drug regimen review. J Manag Care Pharm 2007; 13(1): 28-36.
10. Page RL, Linnebur SA, Bryant LL, Ruscin JM. Inappropriate prescribing in the hospitalized elderly patient: defining the problem, evaluation tools, and possible solutions. Clin Interv Aging 2010; 5: 75-87.
11. McAnaw JJ. Development of novel approaches to demonstrate quality of drug therapy use, PhD thesis, University of Strathclyde, Glasgow, 2002.
12. McAnaw JJ, Hudson S, McGlynn S. Development of an evidence-based medication assessment tool to demonstrate the quality of drug therapy use in patients with heart failure. Int J Pharm Pract 2003; 11(Suppl.): R17, Reference type: abstract.
13. Chinwong S, Reid F, McGlynn S, Hudson S, Flapan A. The need for pharmaceutical care in the prevention of coronary heart disease: an exploratory study in acute myocardial infarction patients. Pharm World Sci 2004; 26(2): 96-101.
14. Ernst A, Kinnear M, Hudson S. Quality of prescribing: a study of guideline adherence of medication in patients with diabetes mellitus. Practical Diabetes Int 2005; 22(8): 285-290.
15. Kamyar M, Johnson BJ, McAnaw JJ, Lemmens-Gruber R, Hudson SA. Adherence to clinical guidelines in the prevention of coronary heart disease in type II diabetes mellitus. Pharm World Sci 2008; 30(1): 120-127.
16. Hakonsen GD, Hudson S, Loennechen T. Design and validation of a medication assessment tool for cancer pain management. Pharm World Sci 2006; 28(6): 342-351.
17. Kulkarni SP, Alexander KP, Lytle B, Heiss G, Peterson ED. Long-term adherence with cardiovascular drug regimens. Am Heart J 2006; 151(1): 185-191.
18. Sud A, Kline-Rogers EM, Eagle KA, et al. Adherence to medications by patients after acute coronary syndromes. Ann Pharmacother 2005; 39(11): 1792-1797.
19. Wei L, Flynn R, Murray GD, MacDonald TM. Use and adherence to beta-blockers for secondary prevention of myocardial infarction: who is not getting the treatment? Pharmacoepidemiol Drug Saf 2004; 13(11): 761-766.
20. Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007; 14(Suppl. 2): S1-113.
21. Task FM, Silber S, Albertsson P, et al. Guidelines for percutaneous coronary interventions: the task force for percutaneous coronary interventions of the European Society of Cardiology. Eur Heart J 2005; 26(8): 804-847.
22. Task FM, Bassand JP, Hamm CW, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: the task force for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes of the European Society of Cardiology. Eur Heart J 2007; 28(13): 1598-1660.
23. Task FM, Mancia G, De Backer G, et al. 2007 guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007; 28(12): 1462-1536.
24. Folketrygdloven. § 5-14 jf blåreseptforskriften §9, punkt 12l med virkning fra 1. juni 2005 [national legislation].
25. Campbell SM, Braspenning J, Hutchinson A, Marshall MN. Improving the quality of health care: research methods used in developing and applying quality indicators in primary care. BMJ 2003; 326(7393): 816-819.
26. Hearnshaw HM, Harker RM, Cheater FM, Baker RH, Grimshaw GM. Expert consensus on the desirable characteristics of review criteria for improvement of health care quality. Qual Saf Health Care 2001; 10(3): 173-178.
27. Cohen J. A coefficient for agreement for nominal scales. Educ Psychol Measure 1960; 20(1): 37-46.
28. Robson C. Real World Research. A Resource for Social Scientists and Practioner-Researchers (2nd edn). Blackwell Publishing: Malden, 2002.
29. WHO/IDF. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO/IDF consultation. 2006.